Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon Cancer
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-15
- Target Recruit Count
- 30
- Registration Number
- NCT04389151
- Locations
- 🇨🇳
Yefeng, Xiamen, Fujian, China
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04385654
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Cancer Hospital of Guangxi Medical University
- Target Recruit Count
- 204
- Registration Number
- NCT04376866
- Locations
- 🇨🇳
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT04374877
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
- Conditions
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 207
- Registration Number
- NCT04365036
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Taizhou Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04363255
- Locations
- 🇨🇳
Enze Hospital, affiliated Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang, China
🇨🇳Haihua, Yang, Taizhou, Zhejiang, China
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
- Target Recruit Count
- 29
- Registration Number
- NCT04357756
- Locations
- 🇦🇺
St George Private Hospital, Kogarah, New South Wales, Australia
🇦🇺Blacktown Hospital, Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇦🇺Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2021-02-18
- Target Recruit Count
- 35
- Registration Number
- NCT04354662
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04338282
ATG-008 Combined With Toripalimab in Advanced Solid Tumors
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 60
- Registration Number
- NCT04337463
- Locations
- 🇨🇳
West China of Sichuan University, Chengdu, Sichuan, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.